Analysing new treatment options for Adenoid Cystic Carcinoma (ACC)
Full project title: Analysis of new therapeutic options for adenoid cystic carcinoma
Tag: New treatment
New and improved therapies are urgently required for ACC, with the 15 year survival rate as low as 40%. One reason for this low rate is that ACC recurrence is common and often spreads to the lungs and perineural space, where the tumour develops chemotherapy resistance which significantly reduces treatment options.
Dr Amanda Swain
Professor Kevin Harrington
Commencement date: October 2016
Length of project:
The Institute of Cancer Research
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.